The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement ...

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

The new mRNA vaccine encodes the receptor-binding domain and the N-terminal domain of the SARS-CoV-2 spike protein ...

U.S. Department of Health and Human Services secretary Robert F. Kennedy, Jr announced on Tuesday that COVID vaccines will be ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

Kennedy Jr. -- are restricting access to COVID shots that were a signature accomplishment of President Trump's first term and ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

The US Food and Drug Administration has approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for individuals aged ...

The US FDA has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for use in adults aged 65 and older.